Akari Therapeutics Plc is an oncology company that develops antibody drug conjugates built around a novel proprietary payload called PH1. The company’s lead candidate AKTX-101 couples PH1 to an antibody that targets the Trop 2 receptor and is intended for solid tumor indications such as lung, breast, bladder, gastric, head and neck, pancreatic and other cancers. A second candidate AKTX-102 links PH1 to an antibody that targets CEACAM5 and is being explored for pancreatic, colon, stomach, esophageal and lung cancers. The PH1 payload exerts its activity by modulating the spliceosome thereby disrupting normal RNA splicing which leads to cancer cell killing and the generation of neoantigens that activate both the innate and adaptive immune systems. The company is conducting IND enabling studies for AKTX-101 with the goal of initiating a first in human Phase 1 trial in late 2026 or early 2027. Akari Therapeutics Plc maintains a small team of employees and relies on third party contract manufacturers for process development and GMP production.

Akari Therapeutics Plc has not yet commercialized any therapeutic product and therefore does not generate product revenue at this stage. The company anticipates that future revenue will arise from the sale of its ADC candidates if they receive regulatory approval, from licensing of its PH1 payload or specific ADC programs to larger biopharmaceutical partners, and from milestone payments and royalties associated with such collaboration agreements. Currently the organization possesses limited internal sales marketing and distribution capabilities and expects to either build a dedicated commercial organization or outsource those functions to third parties upon approval of a product. Manufacturing of clinical and commercial supplies is outsourced to contract development and manufacturing organizations, with WuXi Biologics/XDC having been selected for GMP production of AKTX-101 to support IND enabling activities and future clinical trials. The company’s financial resources are directed toward research and development, preclinical studies, toxicology assessments and the preparation of regulatory submissions rather than toward sales and marketing efforts.

Akari Therapeutics Plc differentiates itself in the crowded ADC landscape by focusing on a payload that acts through a novel biological mechanism rather than the conventional microtubule inhibitor or DNA damaging agent classes used in most approved antibody drug conjugates. The PH1 payload interferes with spliceosome function causing mitotic disruption and direct cytotoxicity while simultaneously producing aberrant RNA species that serve as neoantigens capable of eliciting an immune response involving B cells T cells neutrophils and macrophages. This dual action may overcome common resistance mechanisms seen with standard payloads and may reduce the likelihood of tumor cells ejecting the drug via multidrug resistance transporters because PH1 is not recognized by those pumps. Preclinical data have shown that AKTX-101 demonstrates greater cytotoxicity at lower doses than the approved Trop 2 ADC Trodelvy® in gastric pancreatic and bladder cancer models and that the combination of AKTX-101 with immune checkpoint inhibitors yields synergistic antitumor activity exceeding the additive effect of each agent alone. Competitors in the Trop 2 directed space include established products such as Trodelvy® and Datroway® as well as numerous early stage programs that rely on traditional payloads, whereas Akari Therapeutics Plc’s approach offers a distinct immunological component that could translate into improved durability of response and a better safety profile by avoiding toxicities commonly associated with topoisomerase I inhibitor based ADCs such as interstitial lung disease and hematologic cytopenias.

Akari Therapeutics Plc intends to serve patients who require treatment for solid tumors that overexpress Trop 2 or CEACAM5, including individuals diagnosed with lung breast bladder gastric head and neck pancreatic colon stomach esophageal and other cancers. The company’s therapeutic candidates are designed for administration in hospital oncology clinics and outpatient infusion centers where physicians oversee intravenous delivery of antibody drug conjugates. While the filing does not disclose specific customer names, the typical users of such therapies are oncologists hematologists and other specialists involved in cancer care. In addition to direct patients and healthcare providers, Akari Therapeutics Plc anticipates that biopharmaceutical companies seeking novel ADC technologies or immuno oncology payloads may become counterparties for licensing partnerships joint development arrangements or co marketing agreements thereby expanding the company’s potential customer base beyond the end user setting.